BIOARRAY Therapeutics
BIOARRAY TherapeuticsDiagnostics for effective cancer treatment sooner . . . because breast cancer affects us all.
Members:
Marcia Fournier, PhD; CEO, Founder
Katherine Martin, PhD; CSO, Founder
Chandra Miller Fienen; JD, Founder
David Magee, PhD, VP
|
Industry Focus:
Life Sciences/Healthcare
Contact:
|
About
BIOARRAY Therapeutics is developing innovative molecular diagnostic tests that help women with breast cancer and their doctors identify more effective treatment sooner by predicting chemotherapy response across multiple cancer subtypes. Our test will help reduce the present "trial and error" approach to chemotherapy treatment decisions, helping patients while reducing overall treatment costs.
(98 votes)
@bioarray_cmf
-
BIOARRAY's CEO Marcia Fournier discussed innovation and breast cancer with Brazilian President at the Statehouse. t.co/9ZPKY0ZO
-
@AACR --just was hearing all about the recent OMICS report. Very interesting and very necessary.
-
Supreme Court decision throws Myriad case back to appeals court. -- t.co/AnywUH2s
-
FDA approves Ventana breast cancer test to determine HER2 status faster & w/ more accuracy. t.co/TdnS7J3H
